Issue and repurchase of class C shares
18 juni, 18:00
Uppsala, Sweden – June 18, 2025 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), Orexo AB (publ) announces that the company has resolved to issue and immediately thereafter repurchase 2,446,000 class C shares. The shares are issued and repurchased in accordance with the long-term incentive programmes LTIP 2023, LTIP Stay-on 2023, LTIP 2024, LTIP Stay-on 2024 and LTIP 2025, which were adopted by the annual general meetings 2023, 2024 and 2025, respectively. The size of the share issue has been determined with account taken to Orexo’s total need for share delivery under the company’s long-term incentive programmes hedged with class C shares.
Danske Bank subscribes for the entire issue of new class C shares at a subscription price corresponding to the quota value of the shares. The entire issue of class C shares will thereafter be repurchased by Orexo for the same price per share.
The purpose of the share issue is to enable the future delivery of ordinary shares to participants in LTIP 2023, LTIP Stay-on 2023, LTIP 2024, LTIP Stay-on 2024 and LTIP 2025. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants in LTIP 2023, LTIP Stay-on 2023, LTIP 2024, LTIP Stay-on 2024 and LTIP 2025. The class C shares do not entitle to dividends.
For further information contact:
Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US.
For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
This information is information that Orexo AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on June 18 at 6 pm CEST.
Attachments
Orexo PR Orexo Has Issued C Shares June 18
Ämnen i artikeln
Issue and repurchase of class C shares
18 juni, 18:00
Uppsala, Sweden – June 18, 2025 – Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), Orexo AB (publ) announces that the company has resolved to issue and immediately thereafter repurchase 2,446,000 class C shares. The shares are issued and repurchased in accordance with the long-term incentive programmes LTIP 2023, LTIP Stay-on 2023, LTIP 2024, LTIP Stay-on 2024 and LTIP 2025, which were adopted by the annual general meetings 2023, 2024 and 2025, respectively. The size of the share issue has been determined with account taken to Orexo’s total need for share delivery under the company’s long-term incentive programmes hedged with class C shares.
Danske Bank subscribes for the entire issue of new class C shares at a subscription price corresponding to the quota value of the shares. The entire issue of class C shares will thereafter be repurchased by Orexo for the same price per share.
The purpose of the share issue is to enable the future delivery of ordinary shares to participants in LTIP 2023, LTIP Stay-on 2023, LTIP 2024, LTIP Stay-on 2024 and LTIP 2025. The class C shares will be converted into ordinary shares prior to delivery to qualifying participants in LTIP 2023, LTIP Stay-on 2023, LTIP 2024, LTIP Stay-on 2024 and LTIP 2025. The class C shares do not entitle to dividends.
For further information contact:
Nikolaj Sørensen, President and CEO
Lena Wange, IR & Communications Director
+46 (0)18 780 88 00
ir@orexo.com
About Orexo
Orexo is a Swedish pharmaceutical company with 30 years of experience developing improved pharmaceuticals based on proprietary formulation technologies that meet large medical needs. On the US market, Orexo provides innovative treatment solutions for patients suffering from opioid use disorder. Products targeting other therapeutic areas are developed and commercialized worldwide with leading partners. Total net sales in 2024 amounted to SEK 590 million, and the number of employees 110. Orexo is listed on Nasdaq Stockholm's main list and is available as ADRs (ORXOY) on the OTCQX market in the US.
For more information on Orexo, visit www.orexo.com. You can also follow Orexo on X, LinkedIn, and YouTube.
This information is information that Orexo AB is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication on June 18 at 6 pm CEST.
Attachments
Orexo PR Orexo Has Issued C Shares June 18
Ämnen i artikeln
Fondernas placeringar
Placeras aktieanalyser
-992x558.png&w=3840&q=75)
Aktieråd
-160x160.jpg&w=3840&q=75)
Fondernas placeringar
Placeras aktieanalyser
Mest läst
Aktieråd
Marknadsöversikt
1 DAG %
Senast
1 mån
Privatekonomi med Placeras expert
Affärsvärlden
